Assertio Holdings, Inc. (ASRT)
NASDAQ: ASRT · Real-Time Price · USD
0.6746
-0.0171 (-2.47%)
At close: Mar 31, 2025, 4:00 PM
0.6897
+0.0151 (2.24%)
After-hours: Mar 31, 2025, 5:24 PM EDT
Assertio Holdings Revenue
In the year 2024, Assertio Holdings had annual revenue of $124.96M, down -17.83%. Assertio Holdings had revenue of $32.18M in the quarter ending December 31, 2024, a decrease of -2.43%.
Revenue (ttm)
$124.96M
Revenue Growth
-17.83%
P/S Ratio
0.53
Revenue / Employee
$2,154,500
Employees
58
Market Cap
64.61M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 124.96M | -27.11M | -17.83% |
Dec 31, 2023 | 152.07M | -4.17M | -2.67% |
Dec 31, 2022 | 156.23M | 45.22M | 40.73% |
Dec 31, 2021 | 111.01M | 2.94M | 2.72% |
Dec 31, 2020 | 108.08M | -121.45M | -52.91% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ASRT News
- 11 days ago - Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 - GlobeNewsWire
- 18 days ago - Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Assertio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 26 days ago - Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 - GlobeNewsWire
- 3 months ago - Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - GlobeNewsWire
- 3 months ago - Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - GlobeNewsWire
- 4 months ago - Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio - Business Wire